SCHEMBL2932847

SCHEMBL2932847

O=S(=O)(c1ccccc1)n1c(B(O)O)cc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.51
CA9 Q16790 3/20 0.51
CA2 P00918 1/20 0.51
ALDH1A1 P00352 2/20 0.50
LMNA P02545 2/20 0.50
RECQL P46063 1/20 0.50
MAPT P10636 1/20 0.50
SRC P12931 2/20 0.46
CCR2 P41597 1/20 0.46
HTR6 P50406 2/20 0.45
MEN1 O00255 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 1/20 0.45
NOD1 Q9Y239 5/20 0.44
CXCL8 P10145 1/20 0.44
HDAC3 O15379 2/20 0.44
HDAC4 P56524 2/20 0.44
HDAC1 Q13547 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29953049 1.00 CA12 (0.51) CA12CA9CA2ALDH1A1LMNA
SCHEMBL29951130 0.88 NOD1 (0.57) CA12CA9CA2ALDH1A1CCR2
SCHEMBL17673234 0.88 NOD1 (0.55) CA12CA9CA2ALDH1A1LMNA
SCHEMBL29952922 0.83 ALDH1A1 (0.42) CA12CA9CA2ALDH1A1LMNA
SCHEMBL28059442 0.79 CA12 (0.55) CA12CA9CA2ALDH1A1LMNA
SCHEMBL20746813 0.78 CA12 (0.51) CA12CA9CA2ALDH1A1LMNA
SCHEMBL28228343 0.77 CA12 (0.56) CA12CA9CA2ALDH1A1LMNA
SCHEMBL3563271 0.77 CA12 (0.56) CA12CA9CA2ALDH1A1LMNA
SCHEMBL6864332 0.76 RECQL (0.73) CA12CA9CA2ALDH1A1LMNA
SCHEMBL31599460 0.76 CCR2 (0.72) CA12CA9CA2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8361484-B2 Polymer systems for lung volume reduction therapy AERIS THERAPEUTICS, INC. (US) 2013-01-29 US claimed
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy CANADIAN IMPERIAL BANK OF COMMERCE (CA) 2010-02-18 US claimed
EP-2059227-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY Aeris Therapeutics, Inc. (US) 2009-05-20 EP claimed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 WO claimed
CN-117279636-A Methods and compounds for modulating myotonic muscular dystrophy type 1 设计治疗公司 2023-12-22 CN disclosed
US-10117948-B2 Selective arylation of dichalcogenides in biomolecules MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2018-11-06 US disclosed
US-9845317-B2 Slow release of organoboronic acids in cross-coupling reactions THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2017-12-19 US disclosed
US-20160376260-A1 Slow Release of Organoboronic Acids in Cross-Coupling Reactions THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2016-12-29 US disclosed
WO-2016205798-A1 SELECTIVE ARYLATION OF DICHALCOGENIDES IN BIOMOLECULES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2016-12-22 WO disclosed
US-20160367693-A1 Selective Arylation of Dichalcogenides in Biomolecules NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-12-22 US disclosed
US-9328102-B2 Slow release of organoboronic acids in cross-coupling reactions THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2016-05-03 US disclosed
US-20150315127-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2015-11-05 US disclosed
US-20080102031-A1 Spirocyclic Heterocyclic Derivatives And Methods Of Their Use ADOLOR CORPORATION (US) 2008-05-01 US disclosed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 WO disclosed
WO-2008033299-A2 USE OF N-CONTAINING SPIROCOMPOUNDS FOR THE ENHANCEMENT OF COGNITIVE FUNCTION ADOLOR CORPORATION (US) 2008-03-20 WO disclosed
US-7338962-B2 Spirocyclic heterocyclic derivatives and methods of their use ADOLOR CORPORATION (US) 2008-03-04 US disclosed
US-7338962-B2 Spirocyclic heterocyclic derivatives and methods of their use ADOLOR CORPORATION (US) 2008-03-04 US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
EP-1880993-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-01-23 EP disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 CA12 3948/4885CA9 2744/4885CA2 1129/4885
US-10117948-B2 Selective arylation of dichalcogenides in biomolecules SCLY, SELENOI, PTMS CA12 704/4885CA9 2158/4885CA2 3002/4885
US-20150315127-A1 THERAPEUTIC COMPOUNDS HTR2C, GRK2, GRK3 CA12 4835/4885CA9 4866/4885CA2 3510/4885
US-20160367693-A1 Selective Arylation of Dichalcogenides in Biomolecules SCLY, SELENOI, TPO CA12 693/4885CA9 2082/4885CA2 3241/4885
US-20160376260-A1 Slow Release of Organoboronic Acids in Cross-Coupling Reactions BRS3, CD79B, GRB2 CA12 1830/4885CA9 941/4885CA2 2491/4885
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy GFER, MUC1, CTH CA12 883/4885CA9 1288/4885CA2 2856/4885
US-20080102031-A1 Spirocyclic Heterocyclic Derivatives And Methods Of Their Use OPRK1, OPRD1, OPRL1 CA12 2102/4885CA9 2406/4885CA2 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.